Delivery Order SPE2DR25D9131-SPE2DR26FCPC0
- Not listed
- The Defense Logistics Agency awarded a delivery order valued at $3,046.10 to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler headquartered in Park Ridge, Illinois, for the supply of EXPAREL 133 mg/10 mL vials. The award, issued on October 21, 2025, with an ultimate completion date of November 12, 2025, is structured as a firm fixed-price delivery order with no set-aside designation, indicating the vendor competed in unrestricted federal procurement. This...
- The Defense Logistics Agency awarded a delivery order valued at $26,113.92 to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler based in Park Ridge, Illinois, for the supply of EXPAREL 266 mg/20 ml vials. This firm fixed-price delivery order, issued on October 24, 2025, with an ultimate completion date of November 17, 2025, carries no set-aside designation, indicating the award was made through competitive procurement. The delivery order is issued under DMS...
- The Defense Logistics Agency awarded a delivery order valued at $3,046.10 to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler based in Park Ridge, Illinois, for the supply of EXPAREL 133 mg/10 ml vials. This firm fixed-price delivery order, issued on October 16, 2025, with an ultimate completion date of November 6, 2025, was awarded without set-aside designation, demonstrating the contractor's competitive capability in unrestricted federal procurement. The...
- The Defense Logistics Agency awarded a delivery order valued at $2,436.88 to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler headquartered in Park Ridge, Illinois, for the supply of EXPAREL 133 mg/10 ml vials. The contract is a firm fixed-price delivery order with an ultimate completion date of November 7, 2025, and was awarded on October 17, 2025. This award carries no set-aside designation, demonstrating the vendor's competitive capability in...
- The Defense Logistics Agency awarded a delivery order valued at $7,531.89 to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler based in Park Ridge, Illinois, for the supply of EXPAREL 266 mg/20 ml vials. This firm fixed-price delivery order, awarded on September 12, 2025, with an ultimate completion date of October 3, 2025, represents a discrete purchase under DMS Pharmaceutical Group's larger Indefinite Delivery Contract with the DLA. The contract involves no...
- The Defense Logistics Agency awarded a $25,106.30 firm fixed-price delivery order to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler based in Park Ridge, Illinois, for the supply of EXPAREL 266 mg/20 ml vials. The delivery order, issued on October 27, 2025, with an ultimate completion date of November 18, 2025, carries no set-aside designation, indicating the award was made through unrestricted federal procurement. This delivery order is issued under DMS...
- The Defense Logistics Agency issued a firm fixed-price delivery order valued at $9,044.22 to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler based in Park Ridge, Illinois, for the supply of EXPAREL 133 mg/10 mL vials. This delivery order, awarded on October 20, 2025, represents one of numerous pharmaceutical procurement actions issued to the vendor during October 2025. The award carries no set-aside designation, demonstrating DMS Pharmaceutical Group's...
- The Defense Logistics Agency (DLA) awarded a delivery order valued at $3,655.32 to DMS Pharmaceutical Group Inc. on September 19, 2025, for the supply of EXPAREL (133 mg/10 mL vial). This award represents a firm fixed-price delivery order under DMS Pharmaceutical Group's larger Indefinite Delivery Contract with the DLA's SPE2DB program, a $499.9 billion vehicle established to streamline pharmaceutical procurement for military health facilities. The order is scheduled for completion by October...
- DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler based in Park Ridge, Illinois, was awarded a delivery order on August 4, 2025, for EXPAREL 133 mg/10 ml vials valued at $15,072.20. This firm fixed-price delivery order, which is not associated with a set-aside designation, is funded by the Defense Logistics Agency's Medical Supply Chain division and is scheduled for completion by August 25, 2025. The award leverages DMS Pharmaceutical Group's position as a...
- The Defense Logistics Agency (DLA) Medical Supply Chain awarded a delivery order valued at $37,659.45 to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler based in Park Ridge, Illinois, for the supply of EXPAREL 266 MG/20 ML vials. The contract, awarded on September 9, 2025, with an ultimate completion date of September 30, 2025, utilizes firm fixed-price pricing with no set-aside designation. This delivery order is issued under DMS Pharmaceutical Group's...
- SPE2DR25D9131Indefinite Delivery Contract
- SPE2DR25D9131-SPE2DR26FCPC0Delivery Order
The Defense Logistics Agency awarded a delivery order valued at $3,730.50 to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler based in Park Ridge, Illinois, for the supply of EXPAREL 133 mg/10 ml vials. This firm fixed-price delivery order, issued on October 30, 2025, with an ultimate completion date of November 21, 2025, carries no set-aside designation, demonstrating the contractor's competitive capability in unrestricted federal procurement. The award is issued under DMS Pharmaceutical Group's single-award Indefinite Delivery Contract (IDC) with the Defense Logistics Agency's Pharmaceutical Prime Vendor Global Program Generation V (PPV-G GEN V) initiative, a $30.3 billion acquisition strategy designed to provide comprehensive pharmaceutical and medical supply support to Department of Defense healthcare facilities worldwide. DMS Pharmaceutical Group has established itself as a critical supplier within the federal pharmaceutical supply chain, with substantial contracting activity through the DLA Medical Supply Chain division. The company's product portfolio encompasses branded and generic prescription medications, biologics, vaccines, specialty pharmaceuticals, and medical consumables, with EXPAREL representing a specialty surgical anesthetic product. The underlying IDC contract, designated SPE2DR and awarded on November 13, 2025, carries a ceiling value of $499,999,999 with an ultimate completion date of December 31, 2036, structured as a 30-month base period with three 30-month option periods. This framework positions DMS Pharmaceutical Group as one of multiple regional prime vendor contractors supporting the diverse and specialized pharmaceutical requirements of military healthcare operations globally.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | Not listed | $3.7k | 10/30/25 |